Barbara A. Wood
Net Worth
Last updated:
What is Barbara A. Wood net worth?
The estimated net worth of Ms. Barbara A. Wood is at least $2,416,354 as of 5 Dec 2022. She owns shares worth $96,320 as insider, has earned $10,874 from insider trading and has received compensation worth at least $2,309,160 in SELLAS Life Sciences Group, Inc..
What is the salary of Barbara A. Wood?
Ms. Barbara A. Wood salary is $577,290 per year as Executive Vice President, Gen. Counsel & Sec. in SELLAS Life Sciences Group, Inc..
How old is Barbara A. Wood?
Ms. Barbara A. Wood is 62 years old, born in 1963.
What stocks does Barbara A. Wood currently own?
As insider, Ms. Barbara A. Wood owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Executive Vice President, Gen. Counsel & Sec. | 56,344 | $1.71 | $96,320 |
What does SELLAS Life Sciences Group, Inc. do?
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Barbara A. Wood insider trading
SELLAS Life Sciences Group, Inc.
Ms. Barbara A. Wood has made 2 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently she sold 2,153 units of SLS stock worth $5,576 on 5 Dec 2022.
The largest trade she's ever made was exercising 2,153 units of SLS stock on 5 Dec 2022. As of 5 Dec 2022 she still owns at least 56,344 units of SLS stock.
SELLAS Life Sciences Group key executives
SELLAS Life Sciences Group, Inc. executives and other stock owners filed with the SEC:
- Dr. Angelos M. Stergiou M.D., ScD h.c. (49) Founder, Pres, Chief Executive Officer & Director
- Dr. Dragan Cicic (62) Senior Vice President of Clinical Devel.
- Ms. Barbara A. Wood (62) Executive Vice President, Gen. Counsel & Sec.